Genentech announces full FDA approval for Venclexta combinations for acute myeloid leukemia

This article was originally published here

Venclexta was previously granted provisional approval in this setting under the FDA’s accelerated approval program in November 2018. Today’s FDA approval converts Venclexta’s accelerated approval in this setting

The post Genentech announces full FDA approval for Venclexta combinations for acute myeloid leukemia appeared first on Pharmaceutical Business review.